Gross Profit Summary of Adhera Therapeutics, Inc.

Adhera Therapeutics, Inc.'s latest annual gross profit in 2022 was - USD , down 0.0% from previous year.
Adhera Therapeutics, Inc.'s latest quarterly gross profit in 2023 Q3 was - USD , down 0.0% from previous quarter.
Adhera Therapeutics, Inc. reported a annual gross profit of - USD in annual gross profit 2021, down 0.0% from previous year.
Adhera Therapeutics, Inc. reported a annual gross profit of - USD in annual gross profit 2020, up 100.0% from previous year.
Adhera Therapeutics, Inc. reported a quarterly gross profit of - USD for 2023 Q3, down 0.0% from previous quarter.
Adhera Therapeutics, Inc. reported a quarterly gross profit of - USD for 2023 Q2, down 0.0% from previous quarter.

Annual Gross Profit Chart of Adhera Therapeutics, Inc. (2022 - 1989)

Historical Annual Gross Profit of Adhera Therapeutics, Inc. (2022 - 1989)

Year	Gross Profit	Gross Profit Growth
2022	- USD	0.0%
2021	- USD	0.0%
2020	- USD	100.0%
2019	-157 Thousand USD	58.96%
2018	-382.52 Thousand USD	15.17%
2017	-450.9 Thousand USD	-816.67%
2016	-49.18 Thousand USD	-107.23%
2015	680 Thousand USD	36.0%
2014	500 Thousand USD	-76.36%
2013	2.11 Million USD	-49.85%
2012	4.21 Million USD	88.6%
2011	2.23 Million USD	-9.11%
2010	2.46 Million USD	-83.3%
2009	14.73 Million USD	5060.27%
2008	-297 Thousand USD	-101.65%
2007	18.03 Million USD	-35.89%
2006	28.13 Million USD	278.77%
2005	7.42 Million USD	367.46%
2004	1.58 Million USD	-91.61%
2003	18.94 Million USD	119.39%
2002	8.63 Million USD	311.14%
2001	2.1 Million USD	-53.49%
2000	4.51 Million USD	-1.85%
1999	4.6 Million USD	-41.03%
1998	7.8 Million USD	100.0%
1997	3.9 Million USD	0.0%
1996	- USD	-100.0%
1995	2.9 Million USD	163.64%
1994	1.1 Million USD	27.91%
1993	860 Thousand USD	168.75%
1992	320 Thousand USD	-57.89%
1991	760 Thousand USD	-36.13%
1990	1.19 Million USD	85.94%
1989	640 Thousand USD	77.78%

Year	Gross Profit	Gross Profit Growth
2023 Q1	- USD	0.0%
2023 Q3	- USD	0.0%
2023 Q2	- USD	0.0%
2022 Q4	- USD	0.0%
2022 Q1	- USD	0.0%
2022 Q2	- USD	0.0%
2022 Q3	- USD	0.0%
2022 FY	- USD	0.0%
2021 Q1	- USD	0.0%
2021 Q3	- USD	0.0%
2021 Q2	- USD	0.0%
2021 FY	- USD	0.0%
2021 Q4	- USD	0.0%
2020 Q1	- USD	-100.0%
2020 FY	- USD	100.0%
2020 Q2	- USD	0.0%
2020 Q3	- USD	0.0%
2020 Q4	- USD	0.0%
2019 Q1	-114.05 Thousand USD	74.71%
2019 Q3	-55 Thousand USD	-266.67%
2019 FY	-157 Thousand USD	58.96%
2019 Q4	27 Thousand USD	149.09%
2019 Q2	-15 Thousand USD	86.85%
2018 Q2	- USD	0.0%
2018 Q4	-451 Thousand USD	-759.12%
2018 Q3	68.42 Thousand USD	0.0%
2018 Q1	- USD	100.0%
2018 FY	-382.52 Thousand USD	15.17%
2017 Q2	- USD	0.0%
2017 FY	-450.9 Thousand USD	-816.67%
2017 Q4	-127.93 Thousand USD	0.0%
2017 Q1	- USD	100.0%
2017 Q3	- USD	0.0%
2016 Q1	250 Thousand USD	25.0%
2016 Q4	-300 Thousand USD	-700.0%
2016 Q3	50 Thousand USD	0.0%
2016 FY	-49.18 Thousand USD	-107.23%
2016 Q2	- USD	-100.0%
2015 Q2	400 Thousand USD	0.0%
2015 FY	680 Thousand USD	36.0%
2015 Q3	80 Thousand USD	-80.0%
2015 Q1	- USD	-100.0%
2015 Q4	200 Thousand USD	150.0%
2014 FY	500 Thousand USD	-76.36%
2014 Q4	500 Thousand USD	0.0%
2014 Q3	- USD	0.0%
2014 Q2	- USD	0.0%
2014 Q1	- USD	-100.0%
2013 Q2	315 Thousand USD	0.0%
2013 FY	2.11 Million USD	-49.85%
2013 Q4	1 Million USD	25.0%
2013 Q3	800 Thousand USD	153.97%
2013 Q1	- USD	-100.0%
2012 Q1	131 Thousand USD	-91.85%
2012 FY	4.21 Million USD	88.6%
2012 Q4	1.32 Million USD	19.53%
2012 Q3	1.1 Million USD	-33.29%
2012 Q2	1.65 Million USD	1165.65%
2011 FY	2.23 Million USD	-9.11%
2011 Q1	214 Thousand USD	-77.54%
2011 Q2	129 Thousand USD	-39.72%
2011 Q3	286 Thousand USD	121.71%
2011 Q4	1.6 Million USD	461.89%
2010 Q4	953 Thousand USD	-15.66%
2010 Q3	1.13 Million USD	485.49%
2010 Q2	193 Thousand USD	4.89%
2010 FY	2.46 Million USD	-83.3%
2010 Q1	184 Thousand USD	-11.54%
2009 Q4	208 Thousand USD	225.0%
2009 Q1	14.15 Million USD	7467.38%
2009 Q3	64 Thousand USD	-79.29%
2009 Q2	309 Thousand USD	-97.82%
2009 FY	14.73 Million USD	5060.27%
2008 Q3	328 Thousand USD	117.16%
2008 Q1	1.09 Million USD	-82.71%
2008 FY	-297 Thousand USD	-101.65%
2008 Q2	-1.91 Million USD	-273.89%
2008 Q4	187 Thousand USD	-42.99%
2007 Q4	6.35 Million USD	235.06%
2007 Q3	1.89 Million USD	-60.89%
2007 FY	18.03 Million USD	-35.89%
2007 Q2	4.85 Million USD	-1.66%
2007 Q1	4.93 Million USD	3.31%
2006 FY	28.13 Million USD	278.77%
2006 Q4	4.77 Million USD	-13.68%
2006 Q1	6.47 Million USD	408.96%
2006 Q2	11.34 Million USD	75.17%
2006 Q3	5.53 Million USD	-51.26%
2005 FY	7.42 Million USD	367.46%
2005 Q3	1.22 Million USD	-23.66%
2005 Q4	1.27 Million USD	4.09%
2005 Q2	1.6 Million USD	-51.89%
2005 Q1	3.33 Million USD	140.78%
2004 FY	1.58 Million USD	-91.61%
2004 Q4	1.38 Million USD	1696.1%
2004 Q3	77 Thousand USD	71.11%
2004 Q2	45 Thousand USD	-46.43%
2004 Q1	84 Thousand USD	-90.09%
2003 Q4	848 Thousand USD	160.92%
2003 FY	18.94 Million USD	119.39%
2003 Q1	2.17 Million USD	33.83%
2003 Q3	325 Thousand USD	-97.92%
2003 Q2	15.59 Million USD	618.09%
2002 Q1	1.44 Million USD	827.56%
2002 Q2	3.57 Million USD	147.27%
2002 Q3	1.87 Million USD	-47.6%
2002 Q4	1.62 Million USD	-13.44%
2002 FY	8.63 Million USD	311.14%
2001 FY	2.1 Million USD	-53.49%
2001 Q2	633 Thousand USD	-36.64%
2001 Q4	156 Thousand USD	-77.68%
2001 Q3	699 Thousand USD	10.43%
2001 Q1	999 Thousand USD	-28.08%
2000 FY	4.51 Million USD	-1.85%
2000 Q2	904 Thousand USD	-8.69%
2000 Q1	990 Thousand USD	-1.0%
2000 Q3	1.23 Million USD	36.28%
2000 Q4	1.38 Million USD	12.74%
1999 Q4	1 Million USD	0.0%
1999 Q1	1.5 Million USD	25.0%
1999 Q2	1.1 Million USD	-26.67%
1999 Q3	1 Million USD	-9.09%
1999 FY	4.6 Million USD	-41.03%
1998 Q3	2.1 Million USD	-19.23%
1998 Q2	2.6 Million USD	36.84%
1998 Q1	1.9 Million USD	171.43%
1998 Q4	1.2 Million USD	-42.86%
1998 FY	7.8 Million USD	100.0%
1997 Q3	1.1 Million USD	0.0%
1997 FY	3.9 Million USD	0.0%
1997 Q4	700 Thousand USD	-36.36%
1997 Q2	1.1 Million USD	37.5%
1997 Q1	800 Thousand USD	0.0%
1996 Q2	1.4 Million USD	40.0%
1996 Q1	1 Million USD	66.67%
1996 Q3	1.1 Million USD	-21.43%
1996 FY	- USD	-100.0%
1995 Q2	1 Million USD	42.86%
1995 Q1	700 Thousand USD	16.67%
1995 Q3	800 Thousand USD	-20.0%
1995 Q4	600 Thousand USD	-25.0%
1995 FY	2.9 Million USD	163.64%
1994 Q2	400 Thousand USD	100.0%
1994 Q3	700 Thousand USD	75.0%
1994 FY	1.1 Million USD	27.91%
1994 Q4	600 Thousand USD	-14.29%
1994 Q1	200 Thousand USD	0.0%
1993 Q3	400 Thousand USD	5.26%
1993 FY	860 Thousand USD	168.75%
1993 Q4	200 Thousand USD	-50.0%
1993 Q2	380 Thousand USD	0.0%
1992 FY	320 Thousand USD	-57.89%
1991 FY	760 Thousand USD	-36.13%
1990 FY	1.19 Million USD	85.94%
1989 FY	640 Thousand USD	77.78%

Peer Gross Profit Comparison of Adhera Therapeutics, Inc.

Name	Gross Profit	Gross Profit Difference
Burzynski Research Institute, Inc.	- USD	NaN%
Arch Therapeutics, Inc.	-2439.00 USD	100.0%
Evofem Biosciences, Inc.	11.7 Million USD	100.0%
Nascent Biotech, Inc.	-319.5 Thousand USD	100.0%
Rebus Holdings, Inc.	- USD	NaN%
Santhera Pharmaceuticals Holding AG	119.1 Million USD	100.0%
Qrons Inc.	- USD	NaN%
Adynxx, Inc.	- USD	NaN%
Neon Bloom, Inc.	- USD	NaN%
Northwest Biotherapeutics, Inc.	-25.79 Million USD	100.0%
ProtoKinetix, Incorporated	-48.25 Thousand USD	100.0%
Skye Bioscience, Inc.	-124.25 Thousand USD	100.0%
Eiger BioPharmaceuticals, Inc.	14.99 Million USD	100.0%
Nanobac Pharmaceuticals, Incorporated	3102.00 USD	100.0%
Institute of Biomedical Research Corp.	- USD	NaN%
SQZ Biotechnologies Company	9.79 Million USD	100.0%
Intellipharmaceutics International Inc.	65.72 Thousand USD	100.0%
Propanc Biopharma, Inc.	-34.15 Thousand USD	100.0%
Mesoblast Limited	-35.16 Million USD	100.0%
Marizyme, Inc.	457.7 Thousand USD	100.0%
Genus plc	178.7 Million USD	100.0%
VioQuest Pharmaceuticals, Inc.	- USD	NaN%
Pharming Group N.V.	220.1 Million USD	100.0%
Therapeutic Solutions International, Inc.	62.22 Thousand USD	100.0%
CNBX Pharmaceuticals Inc.	410.16 Thousand USD	100.0%
Nymox Pharmaceutical Corporation	-11 Thousand USD	100.0%
ContraFect Corporation	-154 Thousand USD	100.0%
PsyBio Therapeutics Corp.	-50 Thousand USD	100.0%
Sienna Biopharmaceuticals, Inc.	- USD	NaN%
RegeneRx Biopharmaceuticals, Inc.	76.76 Thousand USD	100.0%
IMV Inc.	-962.29 Thousand USD	100.0%
AXIM Biotechnologies, Inc.	-387.5 Thousand USD	100.0%
MultiCell Technologies, Inc.	49.32 USD	100.0%
ONE Bio Corp.	20.12 Million USD	100.0%
Accustem Sciences Inc.	- USD	NaN%
RVL Pharmaceuticals plc	40.26 Million USD	100.0%
Arno Therapeutics, Inc.	- USD	NaN%
EV Biologics, Inc.	48.9 Thousand USD	100.0%
Q BioMed Inc.	-8988.00 USD	100.0%
Emmaus Life Sciences, Inc.	28.25 Million USD	100.0%
Mosaic ImmunoEngineering Inc.	- USD	NaN%
Biomind Labs Inc.	-15.42 Thousand USD	100.0%
American Oriental Bioengineering, Inc.	44.35 Million USD	100.0%
Provectus Biopharmaceuticals, Inc.	-1.14 Million USD	100.0%
TetraLogic Pharmaceuticals Corporation	- USD	NaN%
Oncotelic Therapeutics, Inc.	70 Thousand USD	100.0%
GlobeStar Therapeutics Corporation	- USD	NaN%
THC Farmaceuticals, Inc.	-4952.00 USD	100.0%
Acro Biomedical Co., Ltd.	140.5 Thousand USD	100.0%
Curative Biotechnology, Inc.	-97.51 Thousand USD	100.0%
GB Sciences, Inc.	-624.00 USD	100.0%
Alpha Cognition Inc.	-86.02 Thousand USD	100.0%
HST Global, Inc.	- USD	NaN%
CSL Limited	7.56 Billion USD	100.0%
Wesana Health Holdings Inc.	- USD	NaN%
Halberd Corporation	-208.00 USD	100.0%
Enzolytics Inc.	30.7 Thousand USD	100.0%
Agentix Corp.	- USD	NaN%
Resverlogix Corp.	- USD	NaN%
Nuo Therapeutics, Inc.	482.43 Thousand USD	100.0%
MetaStat, Inc.	- USD	NaN%
argenx SE	1.1 Billion USD	100.0%
Enzon Pharmaceuticals, Inc.	- USD	NaN%
Endonovo Therapeutics, Inc.	-514.51 Thousand USD	100.0%
RespireRx Pharmaceuticals Inc.	- USD	NaN%
GeneThera, Inc.	- USD	NaN%
Inhibitor Therapeutics, Inc.	- USD	NaN%
AVAX Technologies, Inc.	617.38 Thousand USD	100.0%
Zenith Capital Corp.	- USD	NaN%
Genscript Biotech Corporation	409.55 Million USD	100.0%
Ember Therapeutics, Inc.	- USD	NaN%
Anthera Pharmaceuticals, Inc.	- USD	NaN%
Sigyn Therapeutics, Inc.	-8856.00 USD	100.0%
WPD Pharmaceuticals Inc.	- USD	NaN%
Cotinga Pharmaceuticals Inc.	-83.84 Thousand USD	100.0%
Kadimastem Ltd	-630.13 Thousand USD	100.0%
Helix BioMedix, Inc.	987.98 Thousand USD	100.0%
VitaSpring Biomedical Co. Ltd.	- USD	NaN%
Capstone Therapeutics Corp.	9.61 Million USD	100.0%
BioStem Technologies, Inc.	15.42 Million USD	100.0%
Oncology Pharma Inc.	- USD	NaN%
Reve Technologies, Inc.	- USD	NaN%
LadRx Corporation	-11.83 Thousand USD	100.0%
Cell Source, Inc.	- USD	NaN%
Regen BioPharma, Inc.	176.56 Thousand USD	100.0%
Regen BioPharma, Inc.	176.56 Thousand USD	100.0%
NovAccess Global Inc.	- USD	NaN%
Affymax, Inc.	1.35 Million USD	100.0%
Itoco Inc.	- USD	NaN%
Rasna Therapeutics, Inc.	- USD	NaN%
Pathfinder Cell Therapy, Inc.	- USD	NaN%
Mobile Lads Corp.	- USD	NaN%
CytoDyn Inc.	-29 Thousand USD	100.0%
Claritas Pharmaceuticals, Inc.	- USD	NaN%
NDT Pharmaceuticals Inc.	- USD	NaN%
NanoSphere Health Sciences Inc.	- USD	NaN%
Alseres Pharmaceuticals, Inc.	450.04 Thousand USD	100.0%
SYBLEU INC	11.69 Thousand USD	100.0%
Advanced Proteome Therapeutics Corporation	- USD	NaN%
ImmunoCellular Therapeutics, Ltd.	- USD	NaN%
International Stem Cell Corporation	4.6 Million USD	100.0%
Bioxytran, Inc.	-8285.00 USD	100.0%
GlobeImmune, Inc.	- USD	NaN%
Predictive Technology Group, Inc.	- USD	NaN%
ProText Mobility, Inc.	- USD	NaN%
Cardax, Inc.	- USD	NaN%
VG Life Sciences Inc.	- USD	NaN%
Kaleido Biosciences, Inc.	- USD	NaN%
Advaxis, Inc.	- USD	NaN%
RenovaCare, Inc.	- USD	NaN%
Regnum Corp.	- USD	NaN%
Innovation Pharmaceuticals Inc.	-373 Thousand USD	100.0%
Neutra Corp.	14.33 Thousand USD	100.0%
Windtree Therapeutics, Inc.	-82 Thousand USD	100.0%
PureTech Health plc	-1.6 Million USD	100.0%
Coeptis Therapeutics, Inc.	-1 Million USD	100.0%
IXICO plc	3.27 Million USD	100.0%
IntelGenx Technologies Corp.	-694 Thousand USD	100.0%
Gelesis Holdings, Inc.	-1.79 Million USD	100.0%
CSL Limited	7.7 Billion USD	100.0%
Cellectis S.A.	18 Thousand USD	100.0%

Global Stocks Search

Adhera Therapeutics, Inc. (ATRX)

Gross Profit Summary of Adhera Therapeutics, Inc.

Annual Gross Profit Chart of Adhera Therapeutics, Inc. (2022 - 1989)

Historical Annual Gross Profit of Adhera Therapeutics, Inc. (2022 - 1989)

Peer Gross Profit Comparison of Adhera Therapeutics, Inc.